Baseline characteristics | Before matching | After matching | ||||
---|---|---|---|---|---|---|
Primary Prevention experienced VA(n = 210) | Secondary Prevention (n = 364) | P-value | Primary Prevention experienced VA(n = 173) | Secondary Prevention (n = 173) | P-value | |
Male | 166 (79.0%) | 259 (71.2%) | 0.038 | 135 (78.0%) | 126 (72.8%) | 0.318 |
Age(years) | 62.72 ± 11.83 | 58.30 ± 13.93 | 0.001 | 62.58 ± 11.77 | 64.00 ± 12.80 | 0.115 |
Ischemic heart disease | 57 (27.1%) | 111 (30.5%) | 0.446 | 47 (27.2%) | 61 (35.3%) | 0.131 |
Hypertension | 70 (33.3%) | 104 (28.6%) | 0.258 | 53 (30.6%) | 54 (31.2%) | 0.907 |
Diabetes | 28 (13.3%) | 34 (9.3%) | 0.162 | 21 (12.1%) | 21 (12.1%) | 1.000 |
Stroke | 4 (1.9%) | 7 (1.9%) | 1.000 | 3 (1.7%) | 4 (2.3%) | 1.000 |
Atrial fibrillation | 26 (12.4%) | 33 (9.1%) | 0.253 | 24 (13.9%) | 21 (12.1%) | 0.632 |
LVEF (%) | 33.13 ± 10.64 | 43.18 ± 12.00 | <0.001 | 34.73 ± 10.83 | 36.33 ± 11.00 | 0.116 |
LVEDD (mm) | 64.68 ± 12.94 | 57.83 ± 10.74 | <0.001 | 63.84 ± 13.25 | 62.87 ± 10.80 | 0.707 |
NYHA class III-IV | 129 (61.4%) | 117 (32.1%) | <0.001 | 97 (56.1%) | 95 (54.9%) | 0.829 |
Beta-blockers | 129 (61.4%) | 210 (57.7%) | 0.428 | 107 (61.8%) | 99 (57.2%) | 0.381 |
ACEI/ARB | 88 (43.8%) | 92 (24.2%) | <0.001 | 68 (39.3%) | 60 (34.7%) | 0.373 |
Diuretics | 77 (36.7%) | 69 (19.0%) | <0.001 | 56 (32.4%) | 48 (27.7%) | 0.348 |
Amiodarone | 47 (22.4%) | 129 (35.4%) | 0.001 | 45 (26.0%) | 52 (30.1%) | 0.404 |